Development of MRF for Characterization of Brain Tumors After Radiotherapy

Launched by CASE COMPREHENSIVE CANCER CENTER · Oct 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new MRI technique called Magnetic Resonance Fingerprinting (MRF) to create high-quality images of the brain in just 5 minutes. The goal is to see if this method can help doctors tell the difference between brain areas affected by radiation treatment (radiation necrosis) and those with recurring tumors. Participants will include people who have had radiation therapy and may have these conditions, as well as healthy individuals with no brain issues.

To join the study, healthy participants must not have any history of brain problems, while those with brain tumors need to have confirmed cases of tumor recurrence or radiation necrosis. During the study, participants will have a one-time MRI scan, and there are no additional tests involved. It's important to note that certain individuals, such as those with specific medical devices or conditions that prevent them from undergoing an MRI, will not be eligible. Overall, this trial aims to improve how we visualize and understand brain conditions after treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Healthy Participants:
• • No history of cerebrovascular disease.
• • No cognitive impairments.
• • Able to provide informed consent.
• Inclusion Criteria for Participants with Brain Tumors:
• • Biopsy-proven cases of developed recurrent tumor or radiation necrosis, OR
• • a. PET identified with developed recurrent tumor or radiation necrosis. OR
• • b. Highly suspicious case with developed recurrent tumor or radiation necrosis confirmed by tumor board, attending physician or surgeon.
• • ECOG performance status 0-2.
• • Life expectancy \> 6 months.
• • Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis.
• Inclusion Criteria for Participants with Brain Metastases or Primary Gliomas:
• • Radiology identified with developed primary gliomas tumor or brain metastases, OR
• • a. PET identified with developed gliomas tumor or brain metastases, OR
• • b. Highly suspicious case with developed gliomas tumor or brain metastases confirmed by tumor board
• • Participants must not have received prior radiation or surgical treatment for brain metastases or primary glioma.
• • Age: 21 years and over
• • ECOG performance status 0-2
• • Life expectancy \> 6 months.
• • Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis.
• Exclusion Criteria:
• • Pregnant women OR lactating women
• • Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
• • Participants who cannot go into the MRI scanner due to metal implants and other medical conditions.
• • The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator.
• • Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material.
• • Known history of severe claustrophobia.
• • Participants unable to lay still in the scanner for 30 minutes at a time.